Astrazeneca spinout Entasis off and running with anti-infective portfolio
By Marie Powers
Friday, July 17, 2015
Astrazeneca plc spinout Entasis Therapeutics Inc. has come in from the cold with a portfolio of drugs that previously resided in the pharma's anti-infectives pipeline and a fistful of cash from its erstwhile parent.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.